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Hypoxic-ischaemic encephalopathy remains a global health burden. Despite medical advances and treatment with therapeutic
hypothermia, over 50% of cooled infants are not protected and still develop lifelong neurodisabilities, including cerebral palsy.
Furthermore, hypothermia is not used in preterm cases or low resource settings. Alternatives or adjunct therapies are urgently
needed. Exendin-4 is a drug used to treat type 2 diabetes mellitus that has also demonstrated neuroprotective properties, and is
currently being tested in clinical trials for Alzheimer’s and Parkinson’s diseases. Therefore, we hypothesized a neuroprotective effect
for exendin-4 in neonatal neurodisorders, particularly in the treatment of neonatal hypoxic-ischaemic encephalopathy. Initially, we
confirmed that the glucagon like peptide 1 receptor (GLP1R) was expressed in the human neonatal brain and in murine neurons at
postnatal Day 7 (human equivalent late preterm) and postnatal Day 10 (term). Using a well characterized mouse model of neonatal
hypoxic-ischaemic brain injury, we investigated the potential neuroprotective effect of exendin-4 in both postnatal Day 7 and 10
mice. An optimal exendin-4 treatment dosing regimen was identified, where four high doses (0.5 mg/g) starting at 0 h, then at 12 h,
24 h and 36 h after postnatal Day 7 hypoxic-ischaemic insult resulted in significant brain neuroprotection. Furthermore,
neuroprotection was sustained even when treatment using exendin-4 was delayed by 2 h post hypoxic-ischaemic brain injury.
This protective effect was observed in various histopathological markers: tissue infarction, cell death, astrogliosis, microglial and
endothelial activation. Blood glucose levels were not altered by high dose exendin-4 administration when compared to controls.
Exendin-4 administration did not result in adverse organ histopathology (haematoxylin and eosin) or inflammation (CD68). Despite
initial reduced weight gain, animals restored weight gain following end of treatment. Overall high dose exendin-4 administration was
well tolerated. To mimic the clinical scenario, postnatal Day 10 mice underwent exendin-4 and therapeutic hypothermia treatment,
either alone or in combination, and brain tissue loss was assessed after 1 week. Exendin-4 treatment resulted in significant neuro-
protection alone, and enhanced the cerebroprotective effect of therapeutic hypothermia. In summary, the safety and tolerance of high
dose exendin-4 administrations, combined with its neuroprotective effect alone or in conjunction with clinically relevant hypothermia
make the repurposing of exendin-4 for the treatment of neonatal hypoxic-ischaemic encephalopathy particularly promising.
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Introduction
Hypoxic-ischaemic encephalopathy (HIE) is a serious com-
plication of labour caused by reduced blood flow and
oxygen supply to the neonatal brain. This can result in
mortality for the infant or significant and lasting brain
damage. HIE is a global problem with an estimated inci-
dence of 1.5 per 1000 live births. Fifteen to 20% of HIE
neonates die during the postnatal period, and an additional
25% develop irreversible and lifelong mental and physical
disabilities including cerebral palsy (Shankaran, 2012). In
2010, HIE was associated with 2.4% of the total Global
Burden of Disease (Lee et al., 2013).
The known temporal sequence of events in the brain fol-
lowing hypoxia-ischaemia in rodent models has defined a
therapeutic window of opportunity of up to 8 h based on
a time course of secondary energy failure and other meas-
ures of secondary brain injury (Blumberg et al., 1997;
Gilland et al., 1998a, b). Early interventions have shown
efficacy when initiated early and within this window
(Nijboer et al., 2011). Reducing the body temperature
(hypothermia) of human neonates within 6 h of hypoxia-
ischaemia onset and with duration of 72 h is the only clin-
ically approved treatment (Edwards et al., 2010).
Hypothermia is thought to protect neurons by reducing
cerebral metabolic rate (Rosomoff and Holaday, 1954)
and concentrations of glutamate and nitric oxide
(Thoresen et al., 1997), inhibiting cerebral energy failure,
preserving high-energy phosphates (Thoresen et al., 1995)
and preventing inflammatory cascades (Inamasu et al.,
2000). However, while hypothermia therapy is very pro-
mising, up to 55% of treated neonates cannot be saved
(Gluckman et al., 2005). Therefore, there is a need to de-
velop therapies that are either more effective than hypo-
thermia, or can be used in combination to enhance its
therapeutic efficacy.
Exendin-4 (also known as exenatide) is a small peptide
drug approved by the Food and Drug Administration
(FDA) in 2005 and European Medicines Agency (EMA)
in 2006 for the treatment of type 2 diabetes mellitus. It is
an analogue of the human glucagon-like peptide-1 (GLP-1)
gut hormone peptide that plays a role in regulating blood
sugar levels by enhancing insulin production from the pan-
creas. While GLP-1 has a half-life of 1.5min (Deacon
et al., 1996), exendin-4 can reach 60–90min (Nielsen
et al., 2004), making it of therapeutic value, and is admin-
istered twice daily after meals. The positive neurological
effects of exendin-4 were first recognized by improvements
in neuropathic aspects in type 2 diabetes mellitus patients
under treatment (Grant et al., 2011). Exendin-4 also effi-
ciently crosses the blood–brain barrier (Kastin and
Akerstrom, 2003; Zanotto et al., 2017) and its cellular re-
ceptor (GLP1R) is found throughout the brain (Wei and
Mojsov, 1995). Although there is no definitive unifying
mechanism, in vitro and in vivo studies have suggested
that exendin-4 has neuroprotective, neurotrophic (Perry
et al., 2002), neurogenic (Bertilsson et al., 2008), anti-
inflammatory (Teramoto et al., 2011), anti-apoptotic
(Tews et al., 2009) and mitoprotective (Fan et al., 2010;
Kang et al., 2015) properties. These findings, together with
the excellent safety profile of exendin-4 in patients with
type 2 diabetes mellitus, has led to recent and ongoing
clinical trials examining the neuroprotective properties of
exendin-4 in patients with Parkinson’s (NCT01174810;
NCT01971242; Aviles-Olmos et al., 2013a; Athauda
et al., 2017) and Alzheimer’s disease (NCT01255163).
Recently, the Parkinson’s disease trial has reported that
patients on exendin-4 show a statistically significant im-
provement in clinical motor and cognitive measures com-
pared to control group. This effect persisted 12 weeks after
ending the exendin-4 treatment (Athauda et al., 2017).
Given the need to develop effective treatments for neo-
natal HIE, the encouraging animal and clinical studies sup-
porting the neuroprotective properties of exendin-4 make it
an attractive therapeutic option. Little is known regarding
the use of exendin-4 in perinatal animals, and there are no
neonatal clinical studies. Therefore, we conducted a preclin-
ical assessment of exendin-4 using an established mouse
model of neonatal hypoxia-ischaemia causing widespread
cerebral damage (Carlsson et al., 2012; Rocha-Ferreira
et al., 2015). In this study, we confirmed the presence of
GLP1R in the perinatal human and murine brains. We
demonstrated significant dose-dependent neuroprotective
and anti-inflammatory effect of exendin-4 treatment
that is dose-dependent and the effects of which can be
maintained even when administration is delayed post-
hypoxia-ischaemia. Furthermore, we conducted a toxicity
study to examine the safety of high dose repeat
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administration of exendin-4 in perinatal mice and demon-
strate safety and tolerance to the drug. Finally, we estab-
lished its ability to be used synergistically with therapeutic
hypothermia that enhances neuroprotection and amelior-
ates brain damage.
Materials and methods
Study approval
All UK mice experiments were approved by the Ethics Committee
of the University College London and were carried out by
licensed personnel (PPL PCC436823) in concordance with the
UK Home Office Guidelines [Animals (Scientific procedures)
Act, 1986]. All mice experiments undertaken in Sweden con-
formed to the Swedish Board of Agriculture and were approved
by the Gothenburg Animal Ethics Committee (61-2014 and 01-
2016). CD1 mice (Charles River) were bred in house with a 12-h
light/dark cycle and had free access to food and water. Breeding
cages contained igloo housing with free access to an exercise
plate. Once weekly, enrichment food in the form of dry nuts
and fruits was sprinkled onto the cages to allow foraging. All
animal experiments included male and female littermates ran-
domly allocated to the different experimental groups to reduce
bias and followed the ARRIVE guidelines (Kilkenny et al., 2011).
For the human post-mortem preterm study, brain tissue samples
were collected from Perinatal Pathology autopsy services at
Hammersmith Hospital and St Thomas’s Hospital, London,
UK. Parental consent was received in accordance to the guidelines
of the National Health Services (NHS), UK. Study ethics were
obtained from the Hammersmith and Queen Charlotte’s and
Chelsea Research Ethics Committee, NHS Research Ethics
Services, UK [Post-mortem magnetic resonance imaging study
on developing brain (supported by the Medical Research
Council, UK); ethics number 07/H0707/139].
Blood analysis
Postnatal Day 7 (P7) mice underwent four high doses of exen-
din-4 (0.5 mg/g per dose, Enzo) via intraperitoneal administra-
tion (5 mg/g, 12 h apart). Naı¨ve or saline-injected mice acted as
controls (n = 6 per group). Twelve hours after the last injec-
tion, blood samples taken via cardiac puncture and collected in
EDTA-coated tube. The analysis was performed by MRC
Harwell Clinical Pathology laboratory (Mary Lyon Centre,
UK). Different parameters were obtained: total white blood
cells, neutrophils, lymphocytes, monocytes, eosinophils and
basophils counts, haematocrit, platelets, red blood cells,
haemoglobin and mean corpuscular volume. Blood glucose
levels (mmol/l) were measured using a blood glucose monitor
(CodeFree, SD Biosensor) in naı¨ve controls and mice following
a single exendin-4 high dose administration (0.5 mg/g). Blood
samples were collected via cardiac puncture at 0.5 h, 1 h, 2 h,
and 4 h post-exendin-4 injection.
Cyclic AMP assay
Brains of P7 naı¨ve mice were collected at 2 h, 4 h, 8 h and 12 h
following a single intraperitoneal injection of exendin-4
(0.5 mg/g). Saline-treated controls were collected 2 h post-
injection (n = 4 per group). All samples were processed using
cAMP direct immunoassay kit as per manufacturer’s instruc-
tions (Abcam).
Hypoxia-ischaemia surgery
Human brain maturation equivalent late preterm (P7) and
term (P10) (Semple et al., 2013) CD1 littermate mice were
anaesthetized with isoflurane (5% induction, 1.5% mainten-
ance). The left common carotid artery was permanently
ligated. Following 1 h recovery, pups were placed in a hypoxic
chamber (8% O2, 36
C) for 30min (P7) or 20min (P10).
Hypothermia treatment
Within 10min post-hypoxia-ischaemia, P10 mice underwent a
single high dose of either exendin-4 (0.5 mg/g) or saline and
were placed in individual compartments within a hypothermia
(33C) or normothermia (36C) chamber for 5 h. One probe in
each chamber monitored environmental temperature and one
animal in each chamber was randomly selected to be used as a
temperature-monitoring sentinel to measure core temperature
using a rectal probe (T21, 0.41mm diameter; Physitemp
Instruments). The use of a rectal probe is in agreement with
previous hypothermia studies in mice and rats demonstrating a
good correlation between core body temperature measured this
way and brain temperature in small rodent pups (Thoresen
et al., 1996b). The alternative use of telemetry is promising
but more expensive and technically challenging. Room tem-
perature was also recorded. Computer Software Daisy lab
10.0 (Physitemp Instruments) was used to monitor the tem-
perature, and values from each probe were recorded every
5min (Supplementary Fig. 1). It was decided prior to the
experiment that sentinel mice (n = 8 normothermia, n = 8
hypothermia) were excluded from the final analysis, as re-
straint-associated stress from the rectal probe has shown a
neuroprotective effect (Thoresen et al., 1996a).
Exendin-4 treatment
Different dose regimens of exendin-4 were used to establish
optimum treatment in the P7 hypoxia-ischaemia injury model,
with initiation within the therapeutic window. Animals were
randomized to: (i) saline (n = 14); (ii) one high dose exendin-4
(0.5mg/g) administered immediately after hypoxia-ischaemia
(n = 14); (iii) four high doses of exendin-4 administered every
12h, starting immediately after hypoxia-ischaemia (n = 14);
(iv) four low doses of exendin-4 (0.05mg/g) administered
every 12h, starting immediately after hypoxia-ischaemia
(n = 14); and (v) four doses of exendin-4 administered every
12h, starting with a 2h delay after hypoxia-ischaemia
(n = 14) (Fig. 1A). In the P10 combined exendin-4 (0.5mg/g)
and hypothermia treatment, animal groups consisted of control
normothermia + saline (NT SAL, n = 24), single treatments nor-
mothermia + exendin-4 (NT EX4, n = 25) and hypother-
mia + saline (HT SAL, n = 25), and combined treatment
hypothermia + exendin-4 (HT EX4, n = 25) (Fig. 1B).
Tissue preparation
Highest level of widespread neuronal caspase-3 expression
within the acute injury phase occurs 48 h post-hypoxia-
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ischaemia (Johnston et al., 2011). Therefore, this time point
was chosen for early evaluation of neuropathological markers
in the P7 study. P7 mice were perfused with 4% paraformal-
dehyde (PFA) 48 h post-hypoxia-ischaemia, brains transferred
to 30% sucrose and snap frozen. P10 mice were perfused in
the same manner 7 days after hypoxia-ischaemia, a time point
when the secondary phase of brain injury is completed
(Gilland et al., 1998a). Coronal brain sections (40-mm thick-
ness) starting from the point of fusion of the corpus callosum
were collected onto TBSAF wells. Every 10th section, in a total
of five sections (400 mm apart) per brain underwent histochem-
istry, immunohistochemistry or immunofluorescence. Whole
post-mortem preterm neonatal brains were fixed in 4% forma-
lin for 7 weeks before anatomical positions from the frontal,
occipital, and parietal lobes were selected and processed using
a Leica tissue processor. The blocks were sectioned at 6-mm
thickness using a microtome, mounted onto SuperFrostTM Plus
slides and allowed to dry for 4 days.
Histochemistry
P7 naı¨ve, saline- and high dose exendin-4-treated mice (no
hypoxia-ischaemia, n = 6 per group) were culled 12h after the
last exendin-4 injection (four doses 12h apart). Different organs:
brain, heart, spleen, liver, lung, pancreas and kidney were stained
with haematoxylin and eosin for histopathological assessment.
Immunohistochemistry
Brain sections were treated as previously described (Rocha-
Ferreira et al., 2015). In brief, slides were fixed in 4% PFA,
blocked with 5% goat serum (Sigma-Aldrich) for 30min and
incubated overnight with MAP2 (1:1000, Sigma), alphaM
(1:5000, Serotec), CD68 (1:2000, Biorad), GFAP (1:6000,
Dako) or ICAM1 (1:3000, Pharmingen) antibodies. Sections
were then incubated with appropriate biotinylated secondary
antibody (anti-rat or anti-rabbit; 1:100) for 1 h at room tem-
perature, followed by 1 h incubation with ABC (1:100; Vector)
solution and visualized with 3,30 diaminobenzidene (DAB)/
hydrogen peroxide (Sigma). The reaction was stopped and
washed twice in bidistilled water. Slides were dehydrated by
consecutive immersion in increasing concentrations of ethanol,
isopropanol and xylene, then covered using DEPEX. Post-
mortem neonatal sections were stained as previously shown
(Carlsson et al., 2011). Slides underwent routine deparaffiniza-
tion, followed by 15min 1% hydrogen peroxide/PBS-Tween
incubation before 15min block with 5% goat serum.
Overnight incubation with GLP1R (1:100, Novus Bio) was
followed by 2h room temperature incubation with biotinylated
goat anti-rabbit secondary antibody (1:1000). Sections were
incubated for 1 h with ABC (1:20) and visualized with DAB/
hydrogen peroxide. The reaction was stopped, and sections
covered as described above.
TUNEL staining
Murine brain sections were incubated in 3% hydrogen perox-
ide/methanol (15min) followed by 2h incubation at 37C with
terminal deoxytransferase and deoxyuridine triphosphate solu-
tion (Roche). The reaction was stopped by incubation in ter-
minal deoxynucleotidyl transferase dUTP nick-end labelling
(TUNEL) stop solution for 10min. Slides were incubated in
ABC solution (1 h, room temperature) and visualized using
DAB enhanced with cobalt nickel in the presence of hydrogen
Figure 1 Schematic of different exendin-4 treatment regimens. (A) Schematic of exendin-4 dosing regimen in the late preterm hypoxia-
ischaemia model (P7). (B) Schematic of combining clinically relevant hypothermia and exendin-4 treatment in the term hypoxia-ischaemia model
(P10). Mouse by Iconic from the Noun Project.
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peroxide. The reaction was stopped, and sections covered as
described above.
Immunofluorescence and scanning
confocal microscopy
Naı¨ve P7, P10 and adult 10 week CD1 mice brain sections
(n = 3 per group) were stained by simultaneous overnight incu-
bation with rabbit anti-GLP1R (1:50, Novus Bio) and mouse
anti-NeuN (1:1000, Millipore), mouse anti-GFAP (1:2000,
Millipore) or rat anti-CD68 (1:2000, Bio-Rad) antibodies.
Representative images were captured using a Zeiss LSM710
confocal microscope and Zen software (Carl Zeiss AG). Post-
mortem neonatal sections were simultaneously incubated with
GLP1R (1:100) and NeuN (1:500) antibodies. Sections were
treated with fluorochrome-conjugated secondary antibody
(1:1000, Alexa Fluor

488 and 546) and mounted with a
Fluoromount-G
TM
mounting medium (ThermoFisher Scientific).
Representative images were captured using a Leica SP5 confocal
microscope equipped with LAS-AF software. All images were
processed using Imaris v.9.1 (Bitplane AG). Because of known
difficulties associated with the GLP1R antibodies (Drucker,
2013), negative GLP1R antibody stained sections were also
used for all developmental time points and in both murine
and human tissue (Fig. 2 and Supplementary Fig. 2).
Quantitative polymerase chain
reaction
The distribution of GLP1R gene expression was assessed in
different brain regions: olfactory bulb, cortex, hypothalamus,
thalamus, hippocampus, cerebellum, pons and medulla. Naı¨ve
brains were extracted at P7, P10 and 10 weeks, and RNA was
isolated using RNeasy Mini kit (Qiagen) and first-strand
cDNA was generated using High-Capacity cDNA Reverse
Transcription kit (Applied Biosystems). Quantitative RT-PCR
was carried out using a StepOnePlus (Applied Biosystems)
with the SsoAdvancedTM Universal SYBR Green PCR Core
Reagents Supermix (Bio-Rad). Primers were designed to detect
mouse Glp1r: forward 50-AGACGGTGCAGAAATGGAGA-30;
reverse 50-TGGCGCTTCCGTGAGG-30 and Gapdh housekeep-
ing gene: forward 50-GTTGTCTCCTGCGACTTCA-30; reverse
50- GGTGGTCCAGGGTTTCTTA-30. Data from StepOneTM
software v2.3 were calibrated to Gapdh and the relative quan-
titation of gene expression was performed using the compara-
tive CT method.
Data analysis
Infarct area was measured using ImageJ software (NIH). The
intact Nissl + areas of the isocortex, pyriform cortex, hippocam-
pus, striatum, thalamus and external capsule brain regions were
delineated bilaterally and the ipsilateral regions were subtracted
from the contralateral regions and expressed as percentage
tissue loss. This method assumes that the contralateral hemi-
sphere represents maximal intact area (100%); however, there
are instances where because of potential symmetrical differences
between hemispheres, the intact ipsilateral hemisphere is larger
in area size and the resulting measurement shows a negative
value. TUNEL+ cells were quantified under 20 magnification
in three separate fields per assessed brain region. Microglial
activation was assessed using semi-quantitative score as previ-
ously described (Rocha-Ferreira et al., 2015), with a scale of: 0
(no activation, ramified microglia) to 4 (widespread amoeboid
microglia). GFAP, ICAM1 and CD68 immunoreactivity was
measured by quantitative thresholding image analysis using
Image Pro Premier software (Media Cybernetics) as previously
described (Rocha-Ferreira et al., 2016). In brief, three non-
overlapping RGB images from the assessed brain regions were
captured using a live video camera (Nikon, DS-Fi1) mounted
onto a Nikon eclipse E600 microscope at 40 magnification
for both GFAP and ICAM1 stainings. Similarly, 30 non-
overlapping RBG images from brain, heart, spleen, liver, lung,
pancreas and kidney were captured for CD68 measurements.
The threshold setting was kept constant for all acquired
images. MAP-2 staining was used for quantification of volumet-
ric tissue loss from five brain levels, starting from level 1 (L1,
fusion of corpus callosum) and continuing until level 5 (L5, late
hippocampus), as well as total volumetric tissue loss (Stridh
et al., 2013). Macroscopic score of tissue loss was performed
using a scale comprising of 0, no visible injury; 1, 25%; 2,
50%; and 3, 75% hemispheric injury/loss.
Statistical analysis
Experimental cohorts consisted of 14–25 mice, based on power
calculations as described by Dupont and Plummer (1990). The
levels of significance are 5% with 80% power as a minimum.
The noise and effect size were estimated through our previous
experience and publications using this mouse model (Wang
et al., 2010; Carlsson et al., 2011) and calculations were per-
formed using publicly available software, PS: Power
and Sample Size Calculation v3.1.2, 2014 (http://biostat.mc.
vanderbilt.edu/wiki/Main/PowerSampleSize) (Dupont and
Plummer, 1998). Data were analysed using the GraphPad
Prism v6.0. All assessments were performed blindly.
Average  standard error of the mean (SEM) was recorded
for all data (Supplementary Table 1) and was first analysed
with the Kolmogorov–Smirnov normality test. As the data
did not follow Gaussian distribution, the Kruskal–Wallis
non-parametric test was applied, followed by Dunn’s test
(Supplementary Table 2). *P50.05, **P50.01, ***P5 0.001
and ****P50.0001.
Data availability
All raw data are available from the corresponding author on
request.
Results
GLP1R is expressed in the human and
murine neonatal brain
Firstly, we sought to confirm the presence of GLP1R both in
the human and murine brains. Confocal imaging using anti-
bodies against GLP1R and neural cell-specific markers showed
GLP1R co-localization predominantly in neurons (NeuN) in
all assessed developmental ages: adult (10 weeks), P10 and P7
(Fig. 2A). At 10 weeks of age, co-localization of GLP1R was
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Figure 2 GLP1R expression in the human preterm and murine brain across different developmental ages.
(A) Immunofluorecence and scanning confocal microscopy studies demonstrating GLP1R is expressed in neurons (NeuN) in the mouse brain
at 10 weeks (adult), P10 and P7, (B) with only small colocalization with astrocytes (GFAP) at 10 weeks of age, and (C) no co-localization with
microglia (CD68) cells in any of the different developmental ages. The first row of micrographs (A–C) show negative staining for GLP1R antibody.
(D) Immunofluorescence studies of post-mortem human preterm brain tissue shows co-localization of GLP1R expression in neurons (NeuN) in
the frontal lobe and hippocampus Ammon’s horn, with the first row of micrographs for each human brain region containing negative staining for
GLP1R antibody. A median filter was applied to the images to reduce noise. (E) Relative quantification of GLP1R expression by quantitative PCR
in different brain regions at 10 weeks, (F) P10 and (G) P7 (n = 6 per age group). CBL = cerebellum; CTX = cortex; HIP = hippocampus;
HPT = hypothalamus; MDL = medulla; OB = olfactory bulbs; THL = thalamus. Scale bar = 20 mm in C; 10mm in D.
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observed mostly in neurons but also in astrocytes (GFAP).
This astrocyte co-localization was not observed at P10 and
P7 (Fig. 2B). No microglia (CD68) co-localization with
GLP1R was observed in any of the different developmental
ages (Fig. 2C). Post-mortem neonatal sections showed GLP1R
expression in the frontal lobe and hippocampus Ammon’s
horn. Confocal imaging confirmed specific co-localization
with neurons (NeuN) (Fig. 2D). Quantitative PCR analysis
using primers against Glp1r and control Gapdh mRNA for
normalization of data (Supplementary Fig. 2) revealed
GLP1R expression across the different brain regions exam-
ined in adult (10 weeks) and neonatal (P10 and P7) mice.
Glp1r mRNA was particularly present in the cortex, cerebel-
lum and olfactory bulb of adult (Fig. 2E), P10 (Fig. 2F) and
P7 mice (Fig. 2G), and also in the hippocampus of P10 and
P7 mice.
Exendin-4 reduces brain infarction in
a dose- and time-dependent manner
To assess the efficacy of exendin-4 brain protection against
neonatal hypoxia-ischaemia, tissue infarction was measured
48 h post-insult using different dosing and concentration
regimen, and timing of intervention. Saline-treated hyp-
oxia-ischaemia littermates served as controls (Fig. 3A).
The Nissl measurement as a percentage of tissue loss
showed overall profound and consistent injury in the
ipsilateral hemisphere of saline-treated hypoxia-ischaemia
controls (SAL, 50%  6.9%). A single high dose intraper-
itoneal administration of exendin-4 immediately after hyp-
oxia-ischaemia significantly reduced tissue infarction
(17%  8.6%, P = 0.0279). The same high dose given im-
mediately after hypoxia-ischaemia and then every 12 h over
a 48-h period provided added reduction of brain injury
(2%  1.8%, P = 0.0214). However, dilution of exendin-4
(0.05 mg/g) given in the same four-dose regimen was not
protective (37%  8%) (Fig. 3B). Delaying the first admin-
istration of exendin-4 by 2 h, in the same 12-h apart four
high dose administrations still resulted in a significant
protective effect (11.0%  6.9%, P = 0.0334), with no dif-
ference in protection observed between immediate and
delayed four high dose regimens (Fig. 3C). Breakdown of
Nissl measurements across individually assessed brain
regions showed that immediate start of four high dose
exendin-4 administrations had the highest regional protec-
tion: isocortex (P = 0.0222), pyriform cortex (P = 0.0629),
hippocampus (P = 0.0005) and striatum (P = 0.0064). This
is followed by the same four high dose administrations
started 2 h after hypoxia-ischaemia: isocortex (P = 0.0334),
striatum (P = 0.0069) and thalamus (P = 0.0406). Lastly,
single high dose exendin-4 given immediately after hyp-
oxia-ischaemia also reduced regional brain injury in pyri-
form cortex (P = 0.0013) and striatum (P = 0.0468)
(Supplementary Fig. 3). There were no differences between
the different hypoxia-ischaemia-saline control groups, there-
fore, animals from all saline groups were randomly
pooled. There were no differences between males and fe-
males in response to any of the treatments and the distribu-
tion of the sexes of mice per experiment are listed in
Supplementary Table 3.
Weight gain measurement was performed in all groups.
Following hypoxia-ischaemia, a single high dose administra-
tion of exendin-4 did not cause weight loss; however, there
was a reduced weight gain in comparison to saline controls,
which reached significance at the 36h (P = 0.0212) and 48h
(P = 0.0148) time points post-hypoxia-ischaemia. Both im-
mediate and 2-h delay four high dose exendin-4 treatments
resulted in initial non-significant weight loss when compared
to baseline weight, with visible signs of recovery 48h post-
hypoxia-ischaemia. In the exendin-4 (four doses group) mice
weighed significantly less than the low-dose group at 12h
(P = 0.0150) and 24h (P = 0.0096) time points, and signifi-
cantly less than saline-injected mice at 24 h (P = 0.0074),
36h (P = 0.0315) and 48h (P = 0.0269) post-hypoxia-ischae-
mia (Fig. 3D). There was no exendin-4-mediated modulation
of weight in the 2-h-delayed four-dose treatment (2H) and
low-dose-treated groups. To assess how quickly exendin-4
was crossing the blood–brain barrier and potentially initiating
a cellular response in the CNS, we measured alterations in
cyclic AMP (cAMP) expression, a known second messenger
of GLP1R signalling. Naı¨ve animals were given one high dose
of exendin-4 and cAMP was measured in the brain at 2h,
4h, 8h and 12h. Significantly higher total brain cAMP was
measured at 2h (P = 0.0021) and 4h (P = 0.0281) when com-
pared to saline-injected controls at 2h (Supplementary Fig. 4).
Exendin-4 prevents cell death and
neuroinflammation
Evaluation of cell death as quantification of TUNEL+ cells
48h after late preterm hypoxia-ischaemia demonstrated sub-
stantial overall cell loss in the control saline-treated group
(310.5  62.9) (Fig. 4A). Four administrations of high dose
exendin-4 started either immediately post-hypoxia-ischaemia
or 2 h later significantly reduced the overall number of
TUNEL+ cells (P = 0.0002 and P50.0001, respectively)
(Fig. 4B). Furthermore, this protective effect was significant
across all individually assessed brain regions: isocortex (SAL
versus EX4, P50.0001, SAL versus 2H, P5 0.0001)
(Fig. 4C), pyriform cortex (SAL versus EX4, P = 0.0001,
SAL versus 2H, P = 0.0002) (Fig. 4D), external capsule
(SAL versus EX4, P50.0001, SAL versus 2H,
P5 0.0001) (Fig. 4E), hippocampus (SAL versus EX4,
P = 0.0253, SAL versus 2H, P = 0.0037) (Fig. 4F), striatum
(SAL versus EX4, P5 0.0001, SAL versus 2H, P5 0.0001)
(Fig. 4G) and thalamus (SAL versus EX4, P50.0001, SAL
versus 2H, P = 0.0010) (Fig. 4H). Microglial activation
(alphaM, mb2) was significantly reduced in both the four
administrations of exendin-4 (P = 0.0006) and 2h delayed
intervention cohorts (P5 0.0001) compared to the saline-
treated controls (Fig. 5A and Supplementary Fig. 5). This
effect was observed throughout all assessed brain regions:
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isocortex (SAL versus EX4, P5 0.0001, SAL versus 2H,
P = 0.0024), pyriform cortex (SAL versus EX4, P = 0.0002,
SAL versus 2H, P = 0.0011), hippocampus (SAL versus EX4,
P5 0.0001, SAL versus 2H, P = 0.0005), striatum (SAL
versus EX4, P5 0.0001, SAL versus 2H, P = 0.0001), thal-
amus (SAL versus EX4, P50.0001, SAL versus 2H,
P5 00001) and external capsule (SAL versus EX4,
P5 0.0001, SAL versus 2H, P = 0.0006). Astrogliosis
(GFAP) was substantially suppressed in both the four admin-
istrations of exendin-4 (P = 0.0038) and 2-h delayed inter-
vention cohorts (P = 0.0155) compared to the saline-treated
controls (Fig. 5B and Supplementary Fig. 5). Regional
analysis showed both immediate and 2-h delayed four-dose
regimen treatments had significantly less GFAP in the isocor-
tex (P = 0.0115 and P = 0.0416), hippocampus (P = 0.0006
and P = 0.0011), striatum (P = 0.0279 and P = 0.0412) and
external capsule (P = 0.0004 and P = 0.0005, respectively).
The pyriform cortex of EX4 mice had significantly less astro-
gliosis (P = 0.0551) than SAL-treated hypoxic-ischaemic mice.
Immediate administration of the four doses of exendin-4
showed the highest inhibition of endothelial activation
(ICAM1) (P = 0.0050) (Fig. 5C and Supplementary Fig. 5).
This effect was present in most assessed brain regions: iso-
cortex (P5 0.0001), hippocampus (P = 0.0443), striatum
Figure 3 Evaluation of optimal exendin-4 dose and time treatment regimen in the P7 late preterm model. (A) Representative
whole brain micrographs of the different treatment groups: saline (n = 14, eight male and six females); one high dose exendin-4 (n = 14, eight male
and six female), four high doses exendin-4 (n = 14, seven male and seven female) and four low-doses exendin-4 (n = 14, seven male and seven
female) started immediately after hypoxia-ischaemia, and four high doses exendin-4 initiated 2 h after hypoxia-ischaemia (n = 14, seven male and
seven female). (B) Effect on ipsilateral hemispheric tissue loss of different dose regimen started immediately after hypoxia-ischaemia and
(C) delayed start of exendin-4 treatment. (D) Weight gain over a 48 h period following immediate exendin-4 administration at the different
doses and (E) different time. Data presented as individual animals  SEM and analysed using Kruskal-Wallis Dunn’s test. *P5 0.05, **P5 0.01,
***P5 0.001. ****P5 0.0001. Scale bar = 2 mm. EX-4 = exendin-4; HI = hypoxia-ischaemia.
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(P = 0.0136), thalamus (P = 0.0171) and external capsule
(P = 0.0057). Four doses of exendin-4 administration with a
2-h delay inhibited the overall increase in ICAM1
(P = 0.0356), which was also observed in the isocortex
(P = 0.0004) and external capsule (P = 0.0300).
Repeated high doses of exendin-4
is non-toxic in neonatal mice
The therapeutically optimal exendin-4 dose (0.5mg/g) given
every 12h over a 48-h period in this study are substantially
higher than those used clinically in diabetic patients.
Therefore, we conducted an examination in naı¨ve (no hyp-
oxia-ischaemia) P7 mice for any toxicity or adverse effects.
High dose exendin-4 did not alter blood glucose levels when
compared to saline-treated or naı¨ve controls (0h, 0.5 h, 1 h,
2 h and 4h time points) (Fig. 6A). The exendin-4 four high
dose regimen in naı¨ve animals resulted in reduced weight
gain at 24 h (naı¨ve versus EX4, P = 0.0552, SAL versus
EX4, P = 0.0552) and 36h (naı¨ve versus EX4, P = 0.0558,
SAL versus EX4, P = 0.05598 time points) (third and fourth
injections), with partial recovery to baseline weight measure-
ment (0h time point) by 48h after final injection (Fig. 6B).
As exendin-4 has been shown to modulate peripheral
immune cells (Yanay et al., 2015; He et al., 2017), blood
tests were conducted after completion of the four high
dosing regimen. Counts of various blood cell populations
and biochemistry: total white blood cells (Fig. 6C), neutro-
phils (Fig. 6D), lymphocytes (Fig. 6E), monocytes (Fig. 6F),
eosinophils (Fig. 6G), basophils (Fig. 6H), haematocrit
(Fig. 6I), platelets (Fig. 6J), red blood cells (Fig. 6K), haemo-
globin (Fig. 6L) and mean corpuscular volume (Fig. 6M) in
mice treated with the high dose exendin-4 regimen were all
normal with no significant differences to naı¨ve unadminis-
tered mice and saline-injected mice. Given the systemic ad-
ministration of exendin-4, in addition to the brain we also
harvested the heart, spleen, liver, lung, pancreas and kidney
for analysis. Haematoxylin and eosin staining did not reveal
any obvious fibrosis or abnormalities in cellular or tissue
architecture in mice receiving the high dose exendin-4
Figure 4 Exendin-4 treatment reduces cell death 48h after P7 hypoxia-ischaemia. (A) Hippocampus micrograph representation
with high magnification inserts (40), of saline, immediate and 2 h delayed four high dose exendin-4 treatment. (B) Overall and individual
(C) isocortex, (D) pyriform cortex, (E) external capsule, (F) hippocampus, (G) striatum and (H) thalamus brain regions quantification of
TUNEL + cell death 48 h after hypoxic-ischaemic injury across the three different treatment groups. Data presented as number of TUNEL + cells
per individual animal  SEM and analysed using Kruskal-Wallis Dunn’s test. *P5 0.05, **P5 0.01, ***P5 0.001 and ****P5 0.0001. Scale
bar = 400 mm. HI = hypoxia-ischaemia.
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Figure 5 Exendin-4 suppresses glial cell activation 48h after hypoxia-ischaemia. Overall and regional assessment of microglia acti-
vation (alphaM, mb2) through semi-quantitative score (A), and quantitative immunoreactivity analysis of astrocytes (GFAP) (B) and endothelial
cells (ICAM1) (C). Data presented as individual animals  SEM and analysed using Kruskal-Wallis Dunn’s test. *P5 0.05, **P5 0.01, ***P5 0.001
and ****P5 0.0001.
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regimen when compared to naı¨ve or saline-treated mice
(Fig. 7A). Quantitative threshold image analysis using a
macrophage-specific marker (CD68) did not show any sig-
nificant inflammatory response in any of the organs exam-
ined from the exendin-4-administered mice compared to
controls (Fig. 7B–H and Supplementary Fig. 5).
High dose exendin-4 enhances
hypothermia neuroprotection
Following hypoxia-ischaemia, animals were randomly allocated
into four groups: (i) normothermia and a single saline injection;
(ii) normothermia and a single high dose exendin-4; (iii) hypo-
thermia and a single saline injection; and (iv) hypothermia and
a single high dose exendin-4 (Fig. 8A). The sex of each animal
is shown in Supplementary Table 3. Macroscopic visual scor-
ing of brain injury 7 days post-hypoxia-ischaemia demon-
strated a more pronounced loss of tissue in the
normothermia + saline (NT SAL) control group when com-
pared to normothermia + exendin-4 (NT EX4, P = 0.0003)
and hypothermia + saline (HT SAL, P = 0.0171), as well as
the combined treatment of hypothermia + exendin-4 (HT
EX4, P5 0.0001) groups (Fig. 8B). Additionally, combined
hypothermia + exendin-4 showed significantly less macroscopic
tissue loss when compared to hypothermia treatment + saline
(HT SAL, P = 0.0532). Exendin-4 single high dose either alone
or in combination with hypothermia did not affect weight gain
(Fig. 8C). To more accurately assess tissue loss, volume infarc-
tion was measured. Normothermia mice demonstrated sub-
stantial total volume tissue loss (11.6  1.2 mm3). Exendin-4
Figure 6 Exendin-4 administration blood analysis. (A) Blood glucose measurement at different time points in naı¨ve and treated mice
following high dose (0.5 mg/g) exendin-4 injection (n = 4 per group). (B) Weight measurement in naı¨ve, saline and exendin-4 alone during the four
high dose administration regimen. (C) Total white blood cell (WBC), (D) neutrophils, (E) lymphocytes, (F) monocytes, (G) eosinophils and
(H) basophils counts, (I) haematocrit (HCT), (J) platelets, (K) red blood cells (RBC), (L) haemoglobin and (M) mean corpuscular volume (MCV)
at the end of the treatment regimen. Data presented as individual animals or as mean  SEM and analysed using Kruskal-Wallis Dunn’s test.
*P5 0.05, **P5 0.01, ***P5 0.001 and ****P5 0.0001. EX4 = exendin-4; SAL = saline.
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Figure 7 Histopathological organ assessment. (A) Representative micrographs of haematoxylin and eosin stained brain, including
hippocampus (hip) level and visceral organs: heart, liver, pancreas, spleen, lung and kidney showing no abnormal histopathology in naı¨ve,
saline (SAL) or exendin-4 (EX4) alone treatments. (B) Quantitative immunoreactivity threshold measurements of macrophages (CD68) in the
brain, (C) heart, (D) spleen, (E) liver, (F) lung, (G) pancreas and (H) kidney for the different groups (n = 6 per group). Data presented as individual
animals  SEM and analysed using Kruskal-Wallis Dunn’s test. *P5 0.05, **P5 0.01, ***P5 0.001 and ****P5 0.0001.
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single high dose (3.9  1.4 mm3, P = 0.0003), hypothermia
alone (5.2  1.2 mm3, P = 0.0115) and combined hypothermia
and exendin-4 (1.1  0.6 mm3, P50.0001) treatments sub-
stantially reduced the infarction volume (Fig. 8D). Analysis of
volume loss across different brain levels showed that in level 1,
NT EX4 and HT EX4 animals were significantly protected
(P = 0.0067 and P5 0.0001). All three treatments resulted in
significant protection when assessing levels 2–5: level 2 NT
EX4 (P = 0.0019), HT SAL (P = 0.0466), HT EX4
(P5 0.0001); level 3 NT EX4 (P = 0.0112), HT SAL
(P = 0.0287), HT EX4 (P5 0.0001); level 4 NT EX4
(P = 0.0016), HT SAL (P = 0.0527), HT EX4 (P5 0.0001);
level 5 NT EX4 (P = 0.0006), HT SAL (P = 0.0206), HT
EX4 (P5 0.0001) (Fig. 8E). Additionally, HT EX4 animals
had substantially less volume loss than HT SAL when assessing
levels 1 (P = 0.0093) and 2 (P = 0.0541).
Discussion
There is an enormous unmet clinical need for effective
interventions against neonatal HIE. We have conducted a
Figure 8 Synergistic enhanced neuroprotection following combined exendin-4 and hypothermia treatment in the term
hypoxia-ischaemia model. (A) Whole brain representative micrographs of normothermia + saline control (NT SAL, n = 24, 10 male and
14 female), single treatments normothermia + exendin-4 (NT EX4, n = 25, 12 male and 13 female) and hypothermia + saline (HT SAL, n = 25,
14 male and 11 female), as well as combined hypothermia and exendin-4 treatment (HT EX4, n = 25, 12 male and 13 female) 7 days after P10
hypoxic-ischaemic injury. (B) Macroscopic score evaluation. (C) Weight gain across the different groups. (D) Overall infarct volume and
(E) through different injury levels, where level 1 indicates the most anterior level, as assessed using MAP-2-stained sections from the different
treatments. Data presented as individual animals or as mean  SEM and analysed using Kruskal-Wallis Dunn’s test. *P5 0.05, **P5 0.01,
***P5 0.001 and ****P5 0.0001. Scale bar = 2 mm.
Exendin-4 reduces perinatal brain damage BRAIN 2018: 141; 2925–2942 | 2937
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/141/10/2925/5079387 by R
oyal Veterinary C
ollege user on 07 August 2019
preclinical study of the therapeutic efficacy and safety of
exendin-4 in a perinatal mouse model of HIE. Here we
establish for the first time that exendin-4 treatment after
neonatal HIE is highly neuroprotective. Furthermore, we
demonstrate that exendin-4 can be used in synergy with
hypothermia, the current clinical standard of care for
HIE, to enhance its therapeutic efficacy.
In our late preterm results, intraperitoneal administration of
0.5mg/g exendin-4 as a four-dose 12h interval regimen
started immediately after hypoxia-ischaemia is significantly
neuroprotective. Delaying the start of this exendin-4 treatment
regimen by 2h also significantly protects the immature brain
with no significant difference in efficacy when compared to
immediate administration post-hypoxia-ischaemia. The signifi-
cant therapeutic efficacy was also measured in other readouts
of neuropathology including a reduction of TUNEL+ cell
death and microglia/macrophage, astrocytes and endothelial
cells activation markers remained low in contrast to untreated
hypoxia-ischaemia groups. Our 2h delayed exendin-4 regi-
men results are of particular clinical relevance and may signify
a potentially extended window of opportunity in which thera-
peutic exendin-4 could be administered. In the adult murine
stroke model using transient middle cerebral artery occlusion,
Teramoto et al. (2011) were able to retain reduced infarct
volume only up to 1h delayed administration of high dose
exendin-4.
This study shows that exendin-4 alone or in combination
with therapeutic hypothermia significantly protects the neo-
natal brain against term HIE. Hypothermia is the only
standard treatment of care for term HIE in developed coun-
tries and is not used in preterm infants or in developing
countries. The latter has a high association with infection,
where hypothermia may have limited or even a detrimental
effect (Robertson et al., 2008; Osredkar et al., 2014).
Furthermore, hypothermia is only partially protective, and
alternative or adjunct therapies are needed. Because of the
variability in the efficacy of hypothermia in the neonatal
rodent model of HIE, we administered a single high dose of
exendin-4 in combination with hypothermia to allow clear
dissection of a potential synergistic adjunct role between
both treatments. Exendin-4 administration provided neuro-
protection against tissue loss in the P10 term mouse com-
parable to the P7 single-dose results, demonstrating that the
same dose is applicable for both developmental ages.
Hypothermia alone also proved significantly neuroprotec-
tive; however, the addition of a single dose of exendin-4
treatment enhanced hypothermia protection both in the
macroscopic injury score and regional infarct volume
assessments.
Exendin-4 is an FDA and EMA approved drug used clinic-
ally for the treatment of type 2 diabetes mellitus (Furman,
2012). Epidemiological studies have established comorbidity
links between type 2 diabetes mellitus and several adult
onset neurodegenerative and cerebrovascular disorders,
where patients with type 2 diabetes mellitus have increased
risk of Alzheimer’s disease (Peila et al., 2002), Parkinson’s
disease (Santiago and Potashkin, 2013) and stroke (Putaala
et al., 2011). This suggests shared disease mechanisms, and
inflammation, aberrant insulin and insulin-like growth factor
1 (IGF1) signalling and mitochondria dysfunction have shown
to contribute to pathogenesis of these conditions (Kruyt et al.,
2010; Donath and Shoelson, 2011; Clark et al., 2012; Aviles-
Olmos et al., 2013b). Most neonatal studies rely on extensive
research of adult experimental models, and despite biological
differences, inflammation (Hagberg et al., 2015) and mito-
chondria dysfunction (Hagberg et al., 2014) are also major
hallmarks of HIE. There are other reasonable links between
hypoxia-ischaemia and the aforementioned adult disorders.
Preclinical rat studies have shown neonatal hypoxia-ischaemia
as a precursor to diabetes, metabolic syndrome and stroke
(Mcpherson et al., 2009), and IGF1 treatment offers neuro-
protection after hypoxia-ischaemia (Brywe et al., 2005).
Therefore, exendin-4-mediated prevention of mitochondria
damage and stimulation of mitochondria biogenesis (Fan
et al., 2010), anti-inflammatory properties and sustained neu-
roprotection beyond the period of intervention (Athauda et al.,
2017) make it an attractive therapeutic approach in the treat-
ment of HIE. In fact, exendin-4 has already been used in
neonatal animals to prevent adolescent and adult disorders
without adverse effects. Transient neonatal preconditioning
with exendin-4 in lamb (Gatford et al., 2013) and rat
(Stoffers et al., 2003) intrauterine growth restriction models
reduced both visceral fat accumulation, a risk factor for type 2
diabetes mellitus, and oxidative stress (Raab et al., 2009).
Neonatal exendin-4 protected against juvenile and adult rat
myocardial ischaemic injury and preconditioned mitochondria
(Brown et al., 2010). Its administration in neonatal wild-type
C57BL/6 mice prevented increased adult body weight and fat
mass, and increased energy levels via GLP1R activation (Rozo
et al., 2017).
The optimal exendin-4 dose concentration used in this
study (0.5 mg/g) is significantly higher than in the treatment
of type 2 diabetes mellitus (0.1 mg/kg) and in the ongoing
Alzheimer’s and Parkinson’s disease trials. The doses used
in this study are based on the findings by Teramoto et al.
(2011), which required the same dose concentration or
higher (10, 50 mg/100ml per mouse) to exert protection
against transient middle cerebral artery occlusion
(Teramoto et al., 2011). We observed that reducing the
dose concentration by 10-fold to 0.05mg/g resulted in abo-
lition of the exendin-4 neuroprotective effect in the HIE
model. This high dose requirement may reflect the acute
and rapid nature of the injury. Hypoglycaemia is a serious
risk for infants suffering from HIE, and blood glucose is
continuously monitored in neonatal intensive care units
(Tam et al., 2012). Therefore, we monitored blood glucose
at different time points after high dose exendin-4 injection,
and the known glucose lowering effects of exendin-4 was
not observed when compared to saline-treated/basal level
controls. This differs from many studies where exendin-4
was associated with substantial reduction in blood glucose
levels. However, many of these preclinical exendin-4 studies
use diabetic models, which have altered baseline glucose
(Young et al., 1999). Clinically, exendin-4 is given to
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patients with type 2 diabetes mellitus as an adjunct to met-
formin, sulfonylurea or basal insulin (Inzucchi et al., 2015),
and it is the exendin-4 addition to metformin and/or sulfo-
nylurea that enables type 2 diabetes mellitus patients to
achieve glycaemic control via improvement of b-cell func-
tion (Kendall et al., 2005). These results are compatible
with exendin-4’s positive effect on glucose homeostasis.
Moreover, exendin-4 administration in healthy individuals
reduces fasting glucose levels without reaching hypogly-
caemic levels (Edwards et al., 2001). Our assessment of
any adverse effects to this transient systemically adminis-
tered high dose exendin-4 regimen did not reveal any toxi-
city through blood, macrophage-inflammatory or
histological analyses. Our results indicate that the high
dose regimen used in this study is safe and well-tolerated
in mice. These findings are supported by a pharmacology
and toxicity review of exenatide (Byetta) reporting that
doses of 450 times the clinical dose in normal glycaemic
monkeys produces no hypoglycaemia, neurological signs or
pathology (https://www.accessdata.fda.gov/drugsatfda_
docs/nda/2009/021919s000pharmr.pdf). Chronic toxicity
studies in monkeys administered very high doses of up to
1000 mg/kg over a 28-day period resulted in no mortality.
Any risks are further mitigated as we have advocated high
doses administered once or every 12 h over a limited 48 h
period (for optimal therapy) when the pathological cascade
associated with HIE is most significant. The lack of com-
mercially available kits to measure exendin-4 makes com-
parison of plasma levels in this study with those in humans
difficult. However, the same review shows that a 200mg/kg
subcutaneous administration in mice leads to a Cmax value
of 318 507pg/ml compared to a human that had received
10 mg/subject and a Cmax of 251 pg/ml.
In our study, high dose exendin-4 in post-hypoxic-ischae-
mic injury or naı¨ve mice resulted in an initial weight drop,
with a return to baseline level (0 h time-point equivalent)
48 h after start. However, a 10-fold lower dose of exendin-
4 (0.05 mg/g) given four times had no effect on body weight
when compared to controls, suggesting that this dose might
be too low for exendin-4 to sufficiently activate GLP1R in
the brain of neonates. Interestingly, P10 mice treated with
one high dose exendin-4 used in conjunction with hypo-
thermia showed no weight change in comparison to con-
trols. This could signify that hypothermia may have a
modulating effect on exendin-4-mediated activation of
GLP1R, although not enough to diminish its neuroprotec-
tive effects in the HIE model.
Exendin-4 was administered intraperitoneally and several
studies have shown that it can readily cross the blood–
brain barrier (Kastin and Akerstrom, 2003; Zanotto
et al., 2017) and interact directly with GLP1R in neural
cells. Our measurements of cAMP (a second messenger of
GLP1R) in the brain at regular time intervals following a
single intraperitoneal administration of exendin-4 to naı¨ve
P7 mice showed significantly elevated levels at the earliest
2 h time point. This suggests that exendin-4 rapidly crosses
the blood–brain barrier and initiates a pharmacological
response. GLP1R is expressed in the human (Wei and
Mojsov, 1995), rat (Go¨ke et al., 1995) and mouse
(Hamilton and Ho¨lscher, 2009) brain. Similarly, we have
shown ubiquitous expression of GLP1R throughout the
naı¨ve mouse brain irrespective of developmental age (P7,
P10 and 10 weeks) and confirm for the first time in the
human preterm neonatal brain. In the neonatal period (P7
and P10) GLP1R seemed to predominantly co-localize with
neuronal cells, whereas GLP1R in adult mice also showed
co-localization with astroglia. We believe that this is the
first study to confirm GLP1R expression in the neonatal
mouse brain, and its main co-localization with neurons at
this developmental stage.
The precise mechanisms of action of exendin-4 neuropro-
tection are still not fully understood. Several studies have
demonstrated a multitude of neuroprotective actions, with
exendin-4-mediated PI3K surge in different areas of the
CNS, leading to increase in phosphorylation of AKT via
PI3K signalling pathway. This mechanism of action is
thought to increase the anti- versus pro-apoptotic bcl-2
family protein balance (Brywe et al., 2005; Athauda and
Foltynie, 2016), attenuate neuroinflammation and stabilize
the blood–brain barrier post-transient middle cerebral
artery occlusion in non- (Chen et al., 2016) and diabetic
mice (Li et al., 2016). Intracellular cAMP levels are also
raised in exendin-4-treated post-transient middle cerebral
artery occlusion as a result of increased GLP1R expression
(Teramoto et al., 2011; Kim et al., 2017). Exendin-4 ad-
ministration also increases islet-brain 1, partially inhibits
JNK and attenuates downstream COX-2 and prostaglandin
E2 after transient middle cerebral artery occlusion (Kim
et al., 2017). Exendin-4 treatment has resulted in mitochon-
dria biogenesis (Fan et al., 2010; Kang et al., 2015), pro-
tection from reactive oxygen species (Teramoto et al.,
2011; Li et al., 2013), inflammatory inhibition (Teramoto
et al., 2011), neurogenesis (Bertilsson et al., 2008), neuro-
trophic effects (Perry et al., 2002) and cell survival
(Teramoto et al., 2011; Candeias et al., 2017). These neu-
roprotective effects are of extreme importance in offsetting
the mechanisms of HIE injury.
The current study was designed to assess exendin-4 drug
preclinical safety and efficacy as a standalone therapy, its
capacity to augment therapeutic hypothermia neuroprotec-
tion, and not specifically the exendin-4 mechanisms of
action. However, aspects of our study suggest that exen-
din-4 may act to maintain neuronal viability and modulate
neuroinflammation. Microglia, astroglia and endothelial
cells are a source of inflammatory response and reactive
oxygen species after HIE (Dietrich, 2002; Hagberg et al.,
2015; Rocha-Ferreira et al., 2016). In our study, four high
dose treatments of exendin-4 started either immediately or
2 h post-hypoxia-ischaemia significantly reduced prolifer-
ation of microglia and its morphological change into
phagocytic amoeboid microglia. GFAP expression in astro-
cytes also remained low and there was reduced ICAM1
immunoreactivity. ICAM1 upregulation is associated
with diapedesis, transendothelial migration and further
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recruitment of peripheral inflammatory cells (Dietrich,
2002). In neonatal hypoxia-ischaemia, ICAM1 is also asso-
ciated with alterations of the brain microvasculature and
breakdown of the blood–brain barrier (Lai et al., 2017). Our
ICAM1 results showed increased ICAM1immunoreactivity,
particularly in the areas surrounding the tissue infarction
observed in the hypoxia-ischaemia group, an effect not
observed in the exendin-4-treated groups. This suggests
that exendin-4 treatment prevents breakdown of the
blood–brain barrier. This is in agreement with a study by
Zanotto et al. (2017) where exendin-4 treatment reversed
blood–brain barrier permeability and reduction of blood–
brain barrier-specific proteins in diabetes mellitus rats. The
suggested beneficial effect of reduced activation of these
cells occurs in parallel with significantly reduced tissue in-
farction assessed through Nissl staining and cell death
(TUNEL assay) in exendin-4-treated mice. The neuropro-
tective effect of exendin-4 alone seemed moderately long-
lasting, as seen in the P10 single dose treatment part of the
study. Our studies showed predominant neuronal expres-
sion of GLP1R. Therefore, it cannot be excluded that the
reduced glial cell activation may be secondary to reduced
neurodegeneration. Additionally, high dose exendin-4 ad-
ministration resulted in significantly higher levels of brain
cAMP, suggesting involvement of the cAMP signalling
pathway, also proposed in other studies (Teramoto et al.,
2011; Kim et al., 2017). Interestingly, metformin, another
type 2 diabetes mellitus medication with diverse pharmaco-
logical activities, also ameliorates brain infarction in neo-
natal hypoxic-ischaemic rats (Fang et al., 2017).
This preclinical study in a mouse model of acute peri-
natal HIE is an essential first step to potentially advance
the use of exendin-4 for clinical benefit. Using severe hyp-
oxic-ischaemic injury in both the late preterm and term
models has shown exendin-4’s efficacy in both ages.
Preterm treatment with exendin-4 alone is highly attractive
as therapeutic hypothermia is not common practise at this
age, and the successful 2-h delayed start of exendin-4 treat-
ment offers a larger therapeutic window of opportunity
within which to administer the drug. Exendin-4 term treat-
ment combined with therapeutic hypothermia has provided
enhanced protection as seen in the brain macroscopic score
and regional volume measurement. Other proof of concept
studies of exendin-4 have already been translated into early
clinical trials for neurological diseases such as Alzheimer’s
disease (NCT01255163) and, in particular, Parkinson’s dis-
ease for which initial reports are highly promising
(NCT01174810; NCT01971242; Aviles-Olmos et al.,
2013a; Athauda et al., 2017). This study and these early
clinical trials support the continued investigation of exen-
din-4 for clinical translation as a treatment for HIE.
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